Connecticut
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in Connecticut: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
Connecticut law generally follows federal patent law principles. However, the interpretation and application of patent eligibility can be influenced by state law considerations and public policy interests, particularly in the context of genetic information.
In Connecticut, as in federal law, naturally occurring DNA sequences cannot be patented, but synthetic modifications and methods of using those sequences may be eligible for patent protection.
The court held that genetic testing methods could be patentable if they involve non-naturally occurring products and innovative processes.
The court affirmed that patents on biopharmaceuticals must pass the utility standard and cannot claim natural phenomena.
The case confirmed that methods developed from natural processes can be patented as long as they meet the requirements of novelty and non-obviousness.
Connecticut's approach largely aligns with the federal standard established in Association for Molecular Pathology v. Myriad Genetics, Inc., which limits the patentability of products of nature. However, Connecticut may impose additional requirements reflecting local policy considerations regarding the health and ethical implications of genetic patents.
Questions on the Connecticut bar exam may focus on the implications of Association for Molecular Pathology, especially in discussing patent eligibility and the distinction between natural and synthetic inventions.